ABSTRACT
Background Given the high rates of adverse events in End-stage renal disease (ESRD) patients and as the applications of central haemodynamics (central blood pressure, augmentation index, pulse wave velocity) in dialysis patients have not been fully clarified, we, therefore, will perform a systematic review of central haemodynamics as a predictor of total and cardiovascular mortality and morbidity in the ESRD population.
Methods This protocol is reported according to the PRISMA-P guideline. The databases PubMed, EMBASE, LILACS, Web of Science, and Google Scholar system will be searched and double screening for prospective studies that assessed the prospective association of central haemodynamics parameters with at least one of the pre-specified outcomes in ESRD patients. Discrepancies will be resolved through consensus. A modified version of the Newcastle-Ottawa Quality Assessment Scale of cohort studies will be used. We intend to use the random-effects model, considering at least moderate heterogeneity between studies. If data allow, we will perform a sensitivity analysis to explore potential sources of between-study heterogeneity.
Discussion This systematic review will summarize current evidence about central haemodynamics measures in the ESRD patients and clarify the incremental prognostic value of this diagnostic tool in these patients. Therefore, this systematic review will also be displayed important knowledge gaps in the current literature regarding the possible utility of central haemodynamics indices in ESRD patients.
Systematic review registration This systematic review protocol was submitted to the PROSPERO international registry of systematic reviews (Registration number: CRD42022260824).
Strengths and limitations of this study
→ The PROSPERO registry helps to promote and maintain transparency in the process and to assist in minimizing the risk of bias. Four databases and one additional grey literature source helps ensure more complete coverage of the topic. All the review phases will be peer-reviewed and will be validated by methodological and clinical experts.
→ Central (aortic, carotid) pressures are pathophysiologically more relevant than peripheral pressures for the pathogenesis of cardiovascular (CV) disease. There is a cumulative increase in CVD during the transition from CKD to ESRD: as patients initiate dialysis, there are significant changes in blood pressure, volume status, and circulating solutes, all of which may contribute to increased risk of CVD. Studies did not further analyze the ability of central pressures and indices to predict future events in separated stages of CKD, especially in End-stage renal disease patients (ESRD) patients.
→ This study has limitations. Because heterogeneity is quite common in these systematic reviews, there may be limited scope for meta-analysis. Possibly, the spectrum of patients in different research sites is the main factor, in most cases, but heterogeneity in associations between studies may be difficult to explain.
→ This systematic review will evaluate the evidence related to the Central Haemodynamics (central blood pressure, augmentation index, pulse wave velocity) incremental prognostic value in ESRD patients, which may lower morbidity and mortality and influence its use as a prognostic marker for ESRD patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022260824
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
blguedes{at}gmail.com; felipe1810{at}gmail.com; guilhermeramajo{at}gmail.com; gbvalente99{at}gmail.com; joaovitorscalon13{at}gmail.com; tarikmaf{at}gmail.com; i.g.demarchi{at}ufsc.br;sergioyamada62{at}gmail.com; rogerokawa{at}uol.com.br; jjvteixeira{at}gmail.com
Data Availability
All data generated or analyzed during this study are included in this published article [and its supplementary information files].
List of Abbreviations
- Aix
- Augmentation Index
- AF
- Atrial fibrillation
- AICD
- Automatic implantable cardioverter defibrillator
- BP
- blood pressure
- CHD
- Coronary heart disease
- CKD
- chronic kidney disease
- CRS
- Cardiorenal syndrome
- CV
- Cardiovascular
- CVD
- Cardiovascular disease
- DM
- Diabetes mellitus
- ESRD
- End-stage renal disease
- HD
- Hemodialysis
- HF
- Heart failure
- LILACS
- Latin American and Caribbean Literature in Health Sciences
- MI
- Myocardial infarction
- NOS
- Newcastle-Ottawa Quality Assessment Scale of cohort studies
- PRISMA-P
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols
- PROSPERO
- International registry of systematic reviews
- PP
- Pulse pressure
- PWV
- Pulse wave velocity
- RRT
- Renal replacement therapy
- UC
- Uremic cardiomyopathy